IBRX
$9.18-8.20%
as of close, Oct 16, 2026
☾ AH $9.18 -8.20%
ImmunityBio Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.02%Russell 3000 0.005%US Stock Market 0.004%
IBRX SEC filings (2026)
CIK 1326110 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
554 filings on EDGAR since 2005 · 11 annual, 34 quarterly, 100 current · financial statements · earnings
Latest 10-K
Feb 23, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 4, 2026
quarter to Jun 30, 2026
Latest 8-K
Oct 14, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Last earnings release
Aug 4, 2026
−$0.08 vs −$0.09 · ▼ 2.8%
Filings on file
554
since 2005, 262 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 148-K8-K · FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS DiseaseRegulation FD disclosure
- Oct 5Insider saleSimon Barry J. (Director) sold 25,000 shares for $269K at $10.75 under a 10b5-1 plan
- Oct 2Insider saleCohen Cheryl (Director) sold 81,056 shares for $851K at $10.50 under a 10b5-1 plan
August 2026
July 2026
- Jul 308-K8-K · Regulation FD disclosure
- Jul 2Insider saleCohen Cheryl (Director) sold 131,210 shares for $1.2M at $9.50 under a 10b5-1 plan
- Jul 1Insider saleSelecky Christobel (Director) sold 159,478 shares for $1.4M at $9.02 under a 10b5-1 plan
June 2026
- Jun 30Insider saleSelecky Christobel (Director) sold 1,000 shares for $9,000 at $9.00 under a 10b5-1 plan
- Jun 29Insider saleSelecky Christobel (Director) sold 95,722 shares for $862K at $9.01 under a 10b5-1 plan
- Jun 24Insider saleSimon Barry J. (Director) sold 25,000 shares for $197K at $7.88 under a 10b5-1 plan
- Jun 108-K8-K · Shareholder vote results
- Jun 4Insider saleSimon Barry J. (Director) sold 23,033 shares for $165K at $7.18 under a 10b5-1 plan
May 2026
- May 188-K8-K · ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesMaterial definitive agreement; Regulation FD disclosure
- May 7EarningsEarnings release — EPS −$0.09 vs −$0.08 est. (−12.5%); revenue $44.2M (+168% y/y) 7.4%
- May 7ReportQuarterly report, Q1 2026 — revenue $44.2M (+168% y/y), net income −$632.8M, EPS −$0.62
April 2026
- Apr 30ProxyProxy · Additional proxy materials
- Apr 30ProxyProxy · Proxy statement
- Apr 30ProxyProxy · Annual report to shareholders
- Apr 98-K8-K · ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesResults of operations
- Apr 68-K8-K · ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceRegulation FD disclosure
March 2026
- Mar 318-K8-K · ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy PipelineMaterial definitive agreement; New financial obligation; Regulation FD disclosure; Other events
February 2026
- Feb 24Insider saleSimon Barry J. (Director) sold 75,000 shares for $901K at $12.01 under a 10b5-1 plan
- Feb 23EarningsEarnings release — EPS −$0.06 vs −$0.08 est. (+25.0%); revenue $38.3M (+407% y/y) 13.0%
- Feb 23ReportAnnual report, FY2025 — revenue $113.3M (+668% y/y), net income −$351.4M, EPS −$0.38
- Feb 23Insider saleSimon Barry J. (Director) sold 165,000 shares for $1.7M at $10.25 under a 10b5-1 plan
- Feb 23Insider saleSelecky Christobel (Director) sold 25,000 shares for $250K at $10.00 under a 10b5-1 plan
- Feb 20Insider saleSimon Barry J. (Director) sold 10,000 shares for $93K at $9.25 under a 10b5-1 plan
- Feb 188-K8-K · Other events
January 2026
- Jan 268-K8-K · Material definitive agreement
- Jan 20Insider saleSimon Barry J. (Director) sold 151,967 shares for $1.1M at $6.54–$7.88 under a 10b5-1 plan
- Jan 20Insider saleSelecky Christobel (Director) sold 25,000 shares for $188K at $7.51 under a 10b5-1 plan
- Jan 16Insider saleSelecky Christobel (Director) sold 50,000 shares for $250K at $5.00 under a 10b5-1 plan
- Jan 158-K8-K · Results of operations
- Jan 148-K8-K · Other events
December 2025
- Dec 298-K8-K · Material definitive agreement; Other events
- Dec 158-K8-K · Directors or officers; compensation
- Dec 128-K8-K · Other events
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $9.5M in 15 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 5, 2026Form 4 | Simon Barry J.DirectorSold · $269K · 25,000 sh · 10b5-1 |
| Oct 2, 2026Form 4 | Cohen CherylDirectorSold · $851K · 81,056 sh · 10b5-1 |
| Jul 2, 2026Form 4 | Cohen CherylDirectorSold · $1.2M · 131,210 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Selecky ChristobelDirectorSold · $1.4M · 159,478 sh · 10b5-1 |
| Jun 30, 2026Form 4 | Selecky ChristobelDirectorSold · $9,000 · 1,000 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Selecky ChristobelDirectorSold · $862K · 95,722 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Simon Barry J.DirectorSold · $197K · 25,000 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Simon Barry J.DirectorSold · $165K · 23,033 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Simon Barry J.DirectorSold · $901K · 75,000 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Simon Barry J.DirectorSold · $1.7M · 165,000 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Selecky ChristobelDirectorSold · $250K · 25,000 sh · 10b5-1 |
| Feb 20, 2026Form 4 | Simon Barry J.DirectorSold · $93K · 10,000 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Simon Barry J.DirectorSold · $1.1M · 151,967 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Selecky ChristobelDirectorSold · $188K · 25,000 sh · 10b5-1 |
| Jan 16, 2026Form 4 | Selecky ChristobelDirectorSold · $250K · 50,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 57 transactions
| Date | Insider |
|---|---|
| Oct 2, 2026Form 4 | Cohen CherylDirectorExercise or conversion · $167K · 55,979 sh · 10b5-1 |
| Oct 2, 2026Form 4 | Cohen CherylDirectorExercise or conversion · Stock Option (right to buy) · $0 · 55,979 sh · 10b5-1 |
| Jul 2, 2026Form 4 | Cohen CherylDirectorExercise or conversion · $167K · 55,979 sh · 10b5-1 |
| Jul 2, 2026Form 4 | Cohen CherylDirectorExercise or conversion · Stock Option (right to buy) · $0 · 55,979 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $476K · 159,478 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 159,478 sh · 10b5-1 |
| Jun 30, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $2,983 · 1,000 sh · 10b5-1 |
| Jun 30, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 1,000 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $281K · 95,722 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 95,722 sh · 10b5-1 |
| Jun 9, 2026Form 4 | Clark WesleyDirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Jun 9, 2026Form 4 | Wendel BruceDirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Jun 9, 2026Form 4 | BLASZYK MICHAEL DDirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Jun 9, 2026Form 4 | Cohen CherylDirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Jun 9, 2026Form 4 | MAXWELL LINDADirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Jun 9, 2026Form 4 | Selecky ChristobelDirectorAward · Stock Option (right to buy) · $0 · 65,600 sh |
| Mar 31, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · $25.0M · 4,606,596 sh |
| Mar 31, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · Second Amended and Restate… · — · 0 sh |
| Feb 23, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $75K · 25,000 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 25,000 sh · 10b5-1 |
| Feb 22, 2026Form 4 | Adcock RichardCEO & President · DirectorTax withholding · $675K · 77,560 sh |
| Feb 22, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersTax withholding · $506K · 58,170 sh |
| Feb 22, 2026Form 4 | Sachs David C.Chief Financial OfficerTax withholding · $180K · 20,682 sh |
| Feb 22, 2026Form 4 | Simon Barry J.DirectorTax withholding · $52K · 6,026 sh · 10b5-1 |
| Feb 22, 2026Form 4 | LAUER REGAN JChief Accounting OfficerTax withholding · $15K · 1,673 sh |
| Feb 22, 2026Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · $0 · 152,439 sh |
| Feb 22, 2026Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · Restricted Stock Units · $0 · 152,439 sh |
| Feb 22, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · $0 · 114,329 sh |
| Feb 22, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · Restricted Stock Units · $0 · 114,329 sh |
| Feb 22, 2026Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · $0 · 40,650 sh |
| Feb 22, 2026Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 40,650 sh |
| Feb 22, 2026Form 4 | Simon Barry J.DirectorExercise or conversion · $0 · 15,243 sh · 10b5-1 |
| Feb 22, 2026Form 4 | Simon Barry J.DirectorExercise or conversion · Restricted Stock Units · $0 · 15,243 sh · 10b5-1 |
| Feb 22, 2026Form 4 | LAUER REGAN JChief Accounting OfficerExercise or conversion · $0 · 4,065 sh |
| Feb 22, 2026Form 4 | LAUER REGAN JChief Accounting OfficerExercise or conversion · Restricted Stock Units · $0 · 4,065 sh |
| Feb 10, 2026Form 4 | Adcock RichardCEO & President · DirectorTax withholding · $971K · 140,048 sh |
| Feb 10, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersTax withholding · $822K · 118,560 sh |
| Feb 10, 2026Form 4 | Sachs David C.Chief Financial OfficerTax withholding · $296K · 42,643 sh |
| Feb 10, 2026Form 4 | LAUER REGAN JChief Accounting OfficerTax withholding · $16K · 2,257 sh |
| Feb 10, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · $0 · 274,122 sh |
| Feb 10, 2026Form 4 | SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC5 filersExercise or conversion · Restricted Stock Units · $0 · 274,122 sh |
| Feb 10, 2026Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · $0 · 274,122 sh |
| Feb 10, 2026Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · Restricted Stock Units · $0 · 274,122 sh |
| Feb 10, 2026Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · $0 · 82,236 sh |
| Feb 10, 2026Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 82,236 sh |
| Feb 10, 2026Form 4 | LAUER REGAN JChief Accounting OfficerExercise or conversion · $0 · 5,482 sh |
| Feb 10, 2026Form 4 | LAUER REGAN JChief Accounting OfficerExercise or conversion · Restricted Stock Units · $0 · 5,482 sh |
| Jan 20, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $75K · 25,000 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 25,000 sh · 10b5-1 |
| Jan 16, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · $149K · 50,000 sh · 10b5-1 |
| Jan 16, 2026Form 4 | Selecky ChristobelDirectorExercise or conversion · Stock Option (right to buy) · $0 · 50,000 sh · 10b5-1 |
| Dec 31, 2025Form 4 | Adcock RichardCEO & President · DirectorTax withholding · $35K · 17,510 sh |
| Dec 31, 2025Form 4 | Sachs David C.Chief Financial OfficerTax withholding · $31K · 15,435 sh |
| Dec 31, 2025Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · $0 · 34,483 sh |
| Dec 31, 2025Form 4 | Adcock RichardCEO & President · DirectorExercise or conversion · Restricted Stock Units · $0 · 34,483 sh |
| Dec 31, 2025Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · $0 · 30,397 sh |
| Dec 31, 2025Form 4 | Sachs David C.Chief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 30,397 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 20 filings
| Filed | What it is |
|---|---|
| Oct 14, 20268-K | FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS DiseaseRegulation FD disclosure |
| Aug 4, 202610-Q | Quarterly report, Q2 2026 — revenue $51.2M (+94% y/y), net income −$230.4M, EPS −$0.22 |
| Aug 4, 20268-K | Earnings release — EPS −$0.08 vs −$0.09 est. (+11.1%); revenue $51.2M (+94% y/y) 2.8% |
| Jul 30, 20268-K | Regulation FD disclosure |
| Jun 10, 20268-K | Shareholder vote results |
| May 18, 20268-K | ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesMaterial definitive agreement; Regulation FD disclosure |
| May 7, 202610-Q | Quarterly report, Q1 2026 — revenue $44.2M (+168% y/y), net income −$632.8M, EPS −$0.62 |
| May 7, 20268-K | Earnings release — EPS −$0.09 vs −$0.08 est. (−12.5%); revenue $44.2M (+168% y/y) 7.4% |
| Apr 30, 2026DEFA14A | Additional proxy materials |
| Apr 30, 2026DEF 14A | Proxy statement |
| Apr 30, 2026ARS | Annual report to shareholders |
| Apr 9, 20268-K | ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesResults of operations |
| Apr 6, 20268-K | ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceRegulation FD disclosure |
| Mar 31, 20268-K | ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy PipelineMaterial definitive agreement; New financial obligation; Regulation FD disclosure; Other events |
| Feb 23, 202610-K | Annual report, FY2025 — revenue $113.3M (+668% y/y), net income −$351.4M, EPS −$0.38 |
| Feb 23, 20268-K | Earnings release — EPS −$0.06 vs −$0.08 est. (+25.0%); revenue $38.3M (+407% y/y) 13.0% |
| Feb 18, 20268-K | Other events |
| Jan 26, 20268-K | Material definitive agreement |
| Jan 15, 20268-K | Results of operations |
| Jan 14, 20268-K | Other events |
2025 · 23 filings
| Filed | What it is |
|---|---|
| Dec 29, 20258-K | Material definitive agreement; Other events |
| Dec 15, 20258-K | Directors or officers; compensation |
| Dec 12, 20258-K | Other events |
| Nov 5, 202510-Q | Quarterly report, Q3 2025 — revenue $32.1M (+425% y/y), net income −$67.3M, EPS −$0.07 |
| Nov 5, 20258-K | Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024Results of operations |
| Aug 8, 20258-K | Other events |
| Aug 5, 202510-Q | Quarterly report, Q2 2025 — revenue $26.4M (+2424% y/y), net income −$92.6M, EPS −$0.10 |
| Aug 5, 20258-K | Results of operations |
| Jul 25, 20258-K | Material definitive agreement; Results of operations; Regulation FD disclosure; Other events |
| Jun 20, 20258-K | Directors or officers; compensation; Shareholder vote results |
| May 12, 202510-Q | Quarterly report, Q1 2025 — revenue $16.5M (+41193% y/y), net income −$129.6M, EPS −$0.15 |
| May 12, 20258-K | Results of operations |
| May 5, 20258-K | Other events |
| Apr 30, 2025DEFA14A | Additional proxy materials |
| Apr 30, 2025ARS | Annual report to shareholders |
| Apr 30, 2025DEF 14A | Proxy statement |
| Apr 15, 20258-K | Results of operations |
| Apr 8, 20258-K | Material definitive agreement; Regulation FD disclosure |
| Mar 19, 20258-K | Change of auditor |
| Mar 3, 202510-K | Annual report, FY2024 — revenue $14.7M (+2271% y/y), net income −$413.6M, EPS −$0.62 |
| Mar 3, 20258-K | Results of operations |
| Feb 13, 20258-K | Directors or officers; compensation |
| Feb 7, 20258-K | Directors or officers; compensation |
2024 · 16 filings
| Filed | What it is |
|---|---|
| Dec 11, 20248-K | Material definitive agreement; Other events |
| Dec 10, 20248-K | Other events |
| Nov 19, 20248-K | Other events |
| Nov 12, 202410-Q | Quarterly report, Q3 2024 — revenue $6.1M (+7346% y/y), net income −$85.7M, EPS −$0.14 |
| Nov 12, 20248-K | Results of operations |
| Aug 12, 202410-Q | Quarterly report, Q2 2024 — revenue $1.0M (+2454% y/y), net income −$134.6M, EPS −$0.20 |
| Jul 18, 20248-K | Material definitive agreement |
| Jun 12, 20248-K | Shareholder vote results |
| May 9, 202410-Q | Quarterly report, Q1 2024 — revenue $40K (−89% y/y), net income −$134.1M, EPS −$0.20 |
| Apr 29, 2024DEFA14A | Additional proxy materials |
| Apr 29, 2024DEF 14A | Proxy statement |
| Apr 29, 2024ARS | Annual report to shareholders |
| Apr 23, 20248-K | Regulation FD disclosure; Other events |
| Mar 19, 202410-K | Annual report, FY2023 — revenue $622K (+159% y/y), net income −$583.2M, EPS −$1.15 |
| Feb 26, 20248-K | Directors or officers; compensation; Code of ethics amendment or waiver |
| Jan 2, 20248-K | Material definitive agreement; New financial obligation; Unregistered sale of equity; Other events |
2023 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 9, 202310-Q | Quarterly report, Q3 2023 — revenue $82K (−31% y/y), net income −$95.6M, EPS −$0.19 |
| Aug 8, 202310-Q | Quarterly report, Q2 2023 — revenue $41K (+17% y/y), net income −$137.9M, EPS −$0.32 |
| May 11, 202310-Q | Quarterly report, Q1 2023 — revenue $360K (+2471% y/y), net income −$116.3M, EPS −$0.27 |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEF 14A | Proxy statement |
| Apr 28, 2023ARS | Annual report to shareholders |
| Mar 1, 202310-K | Annual report, FY2022 — revenue $240K (−74% y/y), net income −$416.6M, EPS −$1.04 |
12 current reports (8-K) not listed; the year is on EDGAR.
2022 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 9, 202210-Q | Quarterly report, Q3 2022 — revenue $118K (+79% y/y), net income −$110.9M, EPS −$0.28 |
| Aug 8, 202210-Q | Quarterly report, Q2 2022 — revenue $35K (−90% y/y), net income −$94.6M, EPS −$0.24 |
| May 10, 202210-Q | Quarterly report, Q1 2022 — revenue $14K (−90% y/y), net income −$102.8M, EPS −$0.26 |
| Apr 29, 2022DEFA14A | Additional proxy materials |
| Apr 29, 2022DEF 14A | Proxy statement |
| Mar 1, 202210-K | Annual report, FY2021 — revenue $934K (+54% y/y), net income −$346.8M, EPS −$0.89 |
8 current reports (8-K) not listed; the year is on EDGAR.
2021 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 12, 202110-Q | Quarterly report, Q3 2021 — revenue $66K (−56% y/y), net income −$87.6M, EPS −$0.22 |
| Aug 12, 202110-Q | Quarterly report, Q2 2021 — revenue $339K (−22% y/y), net income −$88.3M, EPS −$0.23 |
| May 14, 202110-Q | Quarterly report, Q1 2021 — revenue $139K (−16% y/y), net income −$79.6M, EPS −$0.21 |
| Apr 29, 2021DEF 14A | Proxy statement |
| Mar 4, 202110-K | Annual report, FY2020 — revenue $605K (−73% y/y), net income −$221.9M, EPS −$0.59 |
| Feb 2, 2021DEFM14A | Merger proxy statement |
17 current reports (8-K) not listed; the year is on EDGAR.
2020 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 9, 202010-Q | Quarterly report, Q3 2020 — revenue $151K (+1158% y/y), net income −$65.6M, EPS −$0.17 |
| Aug 7, 202010-Q | Quarterly report, Q2 2020 — revenue $436K (+2465% y/y), net income −$51.4M |
| May 11, 202010-Q | Quarterly report, Q1 2020 — revenue $165K (+3200% y/y), net income −$37.0M |
| Apr 24, 2020DEF 14A | Proxy statement |
| Mar 25, 202010-K | Annual report, FY2019 — revenue $2.2M (+4585% y/y), net income −$157.8M, EPS −$0.43 |
9 current reports (8-K) not listed; the year is on EDGAR.
2019 · 8 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 5, 201910-Q | Quarterly report, Q3 2019 — revenue $12K (−61% y/y), net income −$15.6M |
| Aug 6, 201910-Q | Quarterly report, Q2 2019 — revenue $17K (+325% y/y), net income −$16.7M |
| May 8, 201910-Q | Quarterly report, Q1 2019 — revenue $5,000 (+0% y/y), net income −$17.9M |
| Apr 26, 2019DEF 14A | Proxy statement |
| Mar 13, 201910-K | Annual report, FY2018 — revenue $47K (+4% y/y), net income −$96.2M |
3 current reports (8-K) not listed; the year is on EDGAR.
2018 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 7, 201810-Q | Quarterly report, Q3 2018 — revenue $31K (+288% y/y), net income −$23.6M |
| Aug 6, 201810-Q | Quarterly report, Q2 2018 — revenue $4,000 (−71% y/y), net income −$27.7M |
| May 7, 201810-Q | Quarterly report, Q1 2018 — revenue $5,000 (−55% y/y), net income −$27.5M |
| Apr 24, 2018DEF 14A | Proxy statement |
| Mar 12, 201810-K | Annual report, FY2017 — revenue $45K (+2% y/y), net income −$96.4M |
2 current reports (8-K) not listed; the year is on EDGAR.
2017 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 7, 201710-Q | Quarterly report, Q3 2017 — revenue $8,000 (−33% y/y), net income −$24.0M |
| Aug 7, 201710-Q | Quarterly report, Q2 2017 — revenue $14K (+17% y/y), net income −$23.5M |
| May 8, 201710-Q | Quarterly report, Q1 2017 — revenue $11K (+83% y/y), net income −$24.5M |
| Apr 28, 2017DEF 14A | Proxy statement |
| Mar 15, 201710-K | Annual report, FY2016 — revenue $44K (−81% y/y), net income −$120.8M |
2 current reports (8-K) not listed; the year is on EDGAR.
2016 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 5 filings — 3 × 8-K, 2 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 42 filings — 29 × 4, 11 × 144, 2 × SCHEDULE 13D/A
| Filed | What it is |
|---|---|
| Oct 6, 20264 | Insider transaction (Form 4) |
| Oct 6, 20264 | Insider transaction (Form 4) |
| Oct 5, 2026144 | Notice of proposed sale (Form 144) |
| Oct 2, 2026144 | Notice of proposed sale (Form 144) |
| Aug 6, 2026SCHEDULE 13D/A | Other filings |
| Jul 6, 20264 | Insider transaction (Form 4) |
| Jul 6, 20264 | Insider transaction (Form 4) |
| Jul 2, 2026144 | Notice of proposed sale (Form 144) |
| Jul 1, 20264 | Insider transaction (Form 4) |
| Jul 1, 2026144 | Notice of proposed sale (Form 144) |
| Jun 30, 2026144 | Notice of proposed sale (Form 144) |
| Jun 29, 2026144 | Notice of proposed sale (Form 144) |
| Jun 26, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 10, 20264 | Insider transaction (Form 4) |
| Jun 5, 20264 | Insider transaction (Form 4) |
| Jun 4, 2026144 | Notice of proposed sale (Form 144) |
| Apr 2, 20264 | Insider transaction (Form 4) |
| Feb 26, 20264 | Insider transaction (Form 4) |
| Feb 25, 2026SCHEDULE 13D/A | Other filings |
| Feb 24, 20264 | Insider transaction (Form 4) |
The newest 25 of 42 shown; the full year is on EDGAR.
2025 · 26 filings — 18 × 4, 3 × 424B5, 1 × 3 and 4 other forms
| Filed | What it is |
|---|---|
| Dec 29, 2025424B5 | Prospectus supplement |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 16, 20253 | Initial insider holdings (Form 3) |
| Nov 10, 2025SCHEDULE 13D/A | Other filings |
| Oct 20, 2025DEF 14C | Other filings |
| Oct 8, 2025PRE 14C | Other filings |
| Jul 28, 2025424B5 | Prospectus supplement |
| Jun 23, 2025S-8 | Employee stock plan registration |
| Jun 20, 20254 | Insider transaction (Form 4) |
| Jun 20, 20254 | Insider transaction (Form 4) |
| Jun 20, 20254 | Insider transaction (Form 4) |
| Jun 20, 20254 | Insider transaction (Form 4) |
| Jun 20, 20254 | Insider transaction (Form 4) |
| Apr 8, 2025424B5 | Prospectus supplement |
| Feb 25, 20254 | Insider transaction (Form 4) |
| Feb 25, 20254 | Insider transaction (Form 4) |
| Feb 25, 20254 | Insider transaction (Form 4) |
| Feb 25, 20254 | Insider transaction (Form 4) |
| Feb 25, 20254 | Insider transaction (Form 4) |
| Feb 12, 20254 | Insider transaction (Form 4) |
| Feb 12, 20254 | Insider transaction (Form 4) |
| Feb 12, 20254 | Insider transaction (Form 4) |
| Feb 12, 20254 | Insider transaction (Form 4) |
| Jan 24, 20254 | Insider transaction (Form 4) |
| Jan 3, 20254 | Insider transaction (Form 4) |
The newest 25 of 26 shown; the full year is on EDGAR.
2024 · 30 filings — 20 × 4, 2 × 424B5, 2 × CORRESP and 6 other forms
| Filed | What it is |
|---|---|
| Dec 16, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Dec 12, 2024424B5 | Prospectus supplement |
| Dec 10, 2024424B5 | Prospectus supplement |
| Jun 20, 2024S-8 | Employee stock plan registration |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| May 2, 2024EFFECT | Other filings |
| Apr 30, 2024CORRESP | Letter to the SEC |
| Apr 17, 2024S-3ASR | Automatic shelf registration |
| Apr 3, 2024UPLOAD | Letter from the SEC staff |
| Mar 29, 2024S-3 | Shelf registration |
| Mar 28, 2024CORRESP | Letter to the SEC |
| Feb 26, 20244 | Insider transaction (Form 4) |
| Feb 26, 20244 | Insider transaction (Form 4) |
| Feb 26, 20244 | Insider transaction (Form 4) |
| Feb 26, 20244 | Insider transaction (Form 4) |
| Feb 26, 20244 | Insider transaction (Form 4) |
| Feb 6, 20244 | Insider transaction (Form 4) |
| Feb 2, 20244 | Insider transaction (Form 4) |
| Feb 2, 20244 | Insider transaction (Form 4) |
The newest 25 of 30 shown; the full year is on EDGAR.
2023 · 37 filings — 22 × 4, 3 × 424B5, 2 × CORRESP and 8 other forms
Counted, not listed; the year is on EDGAR.
2022 · 31 filings — 14 × 4, 3 × 424B5, 2 × 5 and 12 other forms
Counted, not listed; the year is on EDGAR.
2021 · 52 filings — 28 × 4, 6 × 3, 6 × 425 and 11 other forms
Counted, not listed; the year is on EDGAR.
2020 · 32 filings — 21 × 4, 5 × 425, 2 × 424B5 and 3 other forms
Counted, not listed; the year is on EDGAR.
2019 · 17 filings — 10 × 4, 1 × 3, 1 × CORRESP and 5 other forms
Counted, not listed; the year is on EDGAR.
2018 · 23 filings — 20 × 4, 1 × 4/A, 1 × SC 13G and 1 other form
Counted, not listed; the year is on EDGAR.
2017 · 17 filings — 12 × 4, 3 × 5, 1 × 3 and 1 other form
Counted, not listed; the year is on EDGAR.
2016 · 29 filings — 17 × 4, 2 × 3, 2 × SC 13G and 8 other forms
Counted, not listed; the year is on EDGAR.
2015 · 48 filings — 11 × 3, 7 × CORRESP, 6 × 4 and 15 other forms
Counted, not listed; the year is on EDGAR.
2014 · 2 filings — 2 × D
Counted, not listed; the year is on EDGAR.
2009 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
2005 · 1 filing — 1 × REGDEX
Counted, not listed; the year is on EDGAR.
About this data#
ImmunityBio Inc. (IBRX) has 554 filings on EDGAR going back to 2005: 11 annual reports, 34 quarterly reports and 100 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 14, 2026, furnished a press release headed “FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease”. Over the last 13 months insiders sold $9.5M in 15 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been ImmunityBio Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read IBRX's latest 10-K?
- IBRX's latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did IBRX last file an 8-K?
- On Oct 14, 2026 it furnished a press release headed “FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 4, 2026.
- Are IBRX insiders buying or selling?
- Over the last 13 months insiders sold $9.5M in 15 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Simon Barry J. (Director) sold 25,000 shares on Oct 5, 2026 for $269K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has IBRX made?
- 554 filings are on EDGAR under the registrant records that have been ImmunityBio Inc., going back to 2005; 262 of them are insider ownership forms (Forms 3, 4, 5 and 144).